全球癌症疼痛市场 – 行业趋势和 2030 年预测

癌症疼痛市场分析和规模

癌症疼痛的发病率不断上升，预计这将促进市场增长。根据美国国家癌症研究所的数据，截至 2021 年 12 月，约有 20-50% 的癌症患者患有疼痛。随着癌症发病率的上升，人们对该疾病以及相关疼痛的认识也在提高。这些主要市场参与者参与并购、合作和各种新产品的发布，以提升其市场占有率。

 Data Bridge Market Research 分析了 2023-2030 年预测期内癌症疼痛市场的增长率。在上述预测期内，癌症疼痛市场的预期复合年增长率约为 5.10%。2022 年市场价值为 66.842 亿美元，到 2030 年将增长至 99.512 亿美元。除了市场价值、增长率、细分市场、地理覆盖范围、市场参与者和市场情景等市场洞察外，Data Bridge Market Research 团队策划的市场报告还包括深入的专家分析、患者流行病学、渠道分析、定价分析和监管框架。

癌症疼痛市场范围和细分

Market Definition

Cancer pain is often related with different oncology disorders and is one of the major complications of cancer disorder. The nature of cancer pain primarily depends on the type of cancer, stages and intervention such as targeted therapy and chemotherapy used in the treatment of cancer. The cancer pain initiates because of the enlargement of tumor mass reducing on bones, nerves and other organs.

Cancer Pain Market Dynamics

Drivers

• Growing Elderly Population and Unhealthy Lifestyle

With regards to its growing elderly population, the market is anticipated to grow at a highest speed. The Administration for Community Living shows that the percentage of Americans aged 65 years and older to be increased to 21.6% by 2040 from 16% in 2019. The other main factors causing the market enlargement include the huge adoption of a sedentary lifestyle and increased consumption of saturated and trans fats. About 28% of adults or 1.4 billion people are surviving a sedentary lifestyle which is approximately more than 1 in 4 adults worldwide. Thus, this factor increases the trend of cancer and its associated pain.

• Rising Healthcare Expenditure And Government Support

With the increasing pervasiveness of cancer, the wide awareness for the disease and the associated pain is also rising. This is also causing rising healthcare expenditure for diagnosing and treating cancer-associated pain. As perm the OECD, the initial estimates of healthcare spending for a group of 16 OECD countries jumped to around 9.9% of GDP in 2020. Thus, the increasing healthcare expenditure and government support globally is projected to fuel the market growth.

Opportunities

• Increasing Prevalence of Cancer

According to the Centers for Disease Control and Prevention (CDC), approximately 15.5 million cancer survivors were alive in the U.S. in 2016. That figure is expected to rise to more than 20 million by 2026. As per the National Cancer Institute records, as of December 2021, about 20-50% of cancer patients suffer from pain. Thus, this factor boost the cancer pain market.

• Increasing Options of Drugs

The rising options for multiple drugs increase the market growth. Aspirin-like drugs are widely used for bone pain, and pain caused by inflammation. Many people experience stomach problems such as indigestion and bleeding with this kind of medication. Aspirin is usually avoided; as it is too hard on the stomach if taken regularly. Furthermore, paracetamol is essential in cancer pain control. It is generally well-tolerated; do not affect the stomach and won’t thin the blood. It is advantageous to decrease fever and relieve bone pain and is often used along with opioids. Thus, this factor is ​​​​​​​advantageous to the market growth.

 Restraints/Challenges

• High Cost of Treatment

The increasing expenditure related with medications hamper the market growth. These inhibitors cost high and people in the major developing and underdeveloped countries, cause the under treatment of several patients. This hampers the market growth.

This cancer pain market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the cancer pain market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Cancer Pain Market Scope

The cancer pain market is segmented on the basis of drug class, indication, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

• Opioids
• Oxycodone
• Hydrocodone
• NSAIDs
• Ibuprofen
• Naproxen
• Others

Indication

• Lung cancer
• Colorectal Cancer
• Breast Cancer
• Prostate Cancer
• Blood Cancer
• Others

Route of Administration

• Oral
• Parenteral
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Cancer Pain Market Regional Analysis/Insights

The cancer pain market is analyzed and market size insights and trends are provided by drug class, indication, route of administration, end-users and distribution channel as referenced above.

癌症疼痛市场报告涉及的主要国家 有：北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、亚太地区的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区（APAC）的其他地区、中东和非洲（MEA）的其他地区、南美洲的巴西、阿根廷和南美洲其他地区。

由于癌症发病率不断上升、主要市场参与者众多以及先进治疗手段广泛，北美癌症疼痛市场在预测期内一直呈现正增长态势。此外，由于诊断率高且医疗基础设施增强，欧洲被视为第二大增长区域

由于医疗设施高度发达且政府举措增多，亚太地区在市场中占据主导地位。

报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和国内市场监管变化。此外，在提供国家数据预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈竞争或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。   

竞争格局和全球癌痛市场份额分析

癌症疼痛市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对癌症疼痛市场的关注有关

癌症疼痛市场的主要参与者包括：

• Abbvie, Inc（美国）
• 诺华公司（瑞士）
• 梯瓦制药工业有限公司 (以色列)
• 辉瑞公司 (美国)
• Amneal Pharmaceuticals LLC.（美国）
• Aurobindo Pharma（印度）
• 强生私人有限公司（美国）
• 葛兰素史克公司 (英国)
• 太阳制药工业有限公司 (印度)
• Cipla Inc.（美国）
• 益普生制药（法国）
• 赛诺菲（法国）
• 勃林格殷格翰国际有限公司（德国）
• Alembic Pharmaceuticals Limited（印度）
• 鲁冰花（印度）
• Zydus 集团 (印度)
•  Apotex Inc（加拿大）
• Aurobindo Pharma（印度）
• Endo Pharmaceuticals plc（爱尔兰）
• Orexo AB（瑞典
• Mundipharma International（英国）
• 久光制药株式会社 (印度)

SKU-52934